Company intelligence / Profile preview

Juneva Therapeutics

Redwood City, California, United States

Ownership: Private
Development stage: Other

Overview

Juvena Therapeutics is a computational biotech company developing engineered biologics from stem-cell secreted proteins to treat muscle-wasting and metabolic diseases. Its lead asset, JUV-161, is in Phase 1 safety studies for DM1 and sarcopenia, and the company is advancing multiple preclinical programs including JUV-112 for obesity. Juvena has secured FDA orphan drug designation for JUV-161, significant funding, and a major partnership with Eli Lilly for muscle health programs.

Therapeutic areas: EndocrinologyRheumatologyGastroenterologyPulmonologyNeurologyMetabolic Disorders
Modalities: BiologicProteinRecombinant fusion protein
Industry: Biotech

Partnerships

Eli Lilly

Beyond the preview

Go deeper on Juneva Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Juneva Therapeutics.

Explore the full profile